CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 20 target
Drug / intervention
AlloRxbiological
Likely dose
Not stated in record
Key inclusion· 2
  • ✓Diagnosis of non-arteritic ischemic optic neuropathy (NAION)
  • ✓Understanding and willingness to sign informed consent
Key exclusion· 10
  • ✕Active infection
  • ✕Active cancer
  • ✕Chronic multisystem organ failure
  • ✕Pregnancy

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05147701
NCT05147701Phase 1RecruitingMonitorUpdated 14mo ago · Completion was 5mo ago
Slow Enrollment
Long Recruiting
Monitor
CompareCT.gov

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Non-arteritic Ischemic Optic Neuropathy

The Foundation for Orthopaedics and Regenerative Medicine·interventional·Posted Dec 7, 2021·Updated Apr 17, 2025

In Brief

A Phase 1 clinical trial evaluating AlloRx for Eye Diseases and 5 related conditions. Currently recruiting, targeting 20 participants across 2 sites in 2 countries.

Signals

Enrolling slower than its timeline implies

Detailed Summary

This trial will study the safety and efficacy of intravenous and sub-tenon delivery of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of non-arteritic ischemic optic neuropathy

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEye Diseases, Retinitis Pigmentosa, Diabetic Retinopathy, Macular Degeneration, Traumatic Optic Neuropathy, Optic Atrophy
CountriesAntigua and Barbuda, Argentina
Collaborators--

Timeline

Phase 1RecruitingOverdue
20222023202420252026
First PostedDec 7, 2021
Enrollment StartFeb 1, 2022
Primary CompletionJan 1, 2026
TodayJul 1, 2026
Enrollment to primary: 3.9 yearsPosted 4.6 years ago

Interventions

AlloRxbiological

cultured allogeneic adult umbilical cord derived mesenchymal stem cells